|(what is this?)|
Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.
Mechanism of action
CD138 (Syndecan-1) is highly overexpressed on various solid tumors and in hematological malignancies, and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells. The antibody part binds to CD138 on the target cells and then the DM4 kills the cell.
- ImmunoGen, more on DM1/DM4 and the linker used in Indatuximab ravtansine
- Syndecan 1, the protein encoded by SDC1.
- Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients
- Biotest AG: Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|